These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 19070887)

  • 1. Clinical Characteristics and Outcomes of Cyclin D1-Positive AL Amyloidosis.
    Tsushima T; Terao T; Narita K; Fukumoto A; Ikeda D; Kamura Y; Kuzume A; Tabata R; Miura D; Takeuchi M; Matsue K
    Am J Clin Pathol; 2023 Aug; 160(2):157-163. PubMed ID: 36940250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya.
    Mengich I; Rajput S; Malkit R; Moloo Z; Kagotho E; Lalani EN; Mwirigi A
    Front Med (Lausanne); 2023; 10():1177775. PubMed ID: 37250623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Role of Cyclin D1 in Multiple Myeloma: A Systematic Review and Meta-Analysis.
    Jiang Y; Zhang C; Lu L; Wang X; Liu H; Jiang Y; Hong L; Chen Y; Huang H; Guo D
    Technol Cancer Res Treat; 2022; 21():15330338211065252. PubMed ID: 35098809
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review.
    Padhi S; Varghese RG; Ramdas A
    Indian J Med Paediatr Oncol; 2013 Oct; 34(4):283-91. PubMed ID: 24604959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.
    Kyrtsonis MC; Bartzis V; Papanikolaou X; Koulieris E; Georgiou G; Dimou M; Tzenou T; Panayiotidis P
    Appl Clin Genet; 2010; 3():41-51. PubMed ID: 23776351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the mangement of multiple myeloma.
    Kumar L; Vikram P; Kochupillai V
    Natl Med J India; 2006; 19(2):80-9. PubMed ID: 16756196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
    Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
    Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
    Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
    Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
    Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.